Concepedia

Shalini Singh

SS

Statistics

Publications

8

Citations

542

H-Index

8

Active since

2000

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Shalini Singh is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and surgery.

Publications per year

2000–2022

8

Publications

8

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity

Yared Hailemichael, Daniel H. Johnson, Noha Abdel‐Wahab et al. · Cancer Cell · 2022 · 344 citations · Full text

, , +14

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial

Ivana Šestak, Shalini Singh, Jack Cuzick et al. · The Lancet Oncology · 2014 · 69 citations · Full text

, , +17

Hepatitis B, C and Human Immunodeficiency Virus Infections in Multiply-injected Kala-azar Patients in Delhi

Shalini Singh · Scandinavian Journal of Infectious Diseases · 2000 · 31 citations

, , +11

Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.

Ahmed O. Kaseb, Dan G. Duda, Hop Sanderson Tran Cao et al. · Journal of Clinical Oncology · 2020 · 28 citations

, , +17

Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.

Ahmed O. Kaseb, Hop Sanderson Tran Cao, Yehia I. Mohamed et al. · Journal of Clinical Oncology · 2020 · 28 citations

, , +16

1–5 of 8